A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide autogel in patients with acromegaly previously treated with octreotide

Endocrine Practice

Volumn 16, Issue 2, 2010, Pages 191-197

  Kelly, Phillip ^a   Maher, Kathy T ^a   Chew, Shern L ^a   Monson, John P ^a   Grossman, Ashley B ^a   Jenkins, Paul J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; LONG ACTING DRUG; OCTREOTIDE; SOMATOMEDIN C; CYCLOPEPTIDE; DRUG DERIVATIVE; SOMATOSTATIN;

ABDOMINAL DISCOMFORT; ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACE PAIN; FEMALE; FLATULENCE; GEL; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; INJECTION SITE SWELLING; INSULIN BLOOD LEVEL; MALE; OPEN STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ACROMEGALY; ADULT; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 77953918290     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09184.OR     Document Type: Article

References (25)

1. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab. 1995;80:3267-3272.
2. Giusti M, Gussoni G, Cuttica CM, Giordano G (Italian Multicenter Slow Release Lanreotide Study Group). Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. J Clin Endocrinol Metab. 1996; 81:2089-2097. (Pubitemid 26175931)
3. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab. 1997;82:18-22. (Pubitemid 27021263)
4. Lancranjan I, Atkinson AB (Sandostatin LAR Group). Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Pituitary. 1999;1:105-114.
5. Verhelst JA, Pedroncelli AM, Abs R, et al. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol. 2000;143:577-584.
6. Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Longterm safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab. 2002;87:4142-4146.
7. Caron P, Bex M, Cullen DR, et al (Group for Lanreotide Autogel Long-Term Study on Acromegaly). One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf). 2004;60:734-740. (Pubitemid 38788082)
8. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002;87:99-104. (Pubitemid 34084677)
9. Ciccarelli A, Daly A, Beckers A. Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium. Treat Endocrinol. 2004;3:77-81. (Pubitemid 38337558)
10. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004;151:317-324. (Pubitemid 39307318)
11. van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol. 2004;150:489-495. (Pubitemid 38584699)
12. Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of lanreotide (lanreotide Autogel). Exp Clin Endocrinol Diabetes. 2005;113:139-144. (Pubitemid 40516354)
13. Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf). 2006;64:209-214.
14. Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B (Lanreotide Acromegaly Study Group). Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf). 2008;69:299-305. (Pubitemid 352009031)
15. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93:2957-2968.
16. Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol. 2004;150:473-480. (Pubitemid 38584697)
17. Morrell DJ, Dadi H, More J, et al. A monoclonal antibody to human insulin-like growth factor-I: characterization, use in radioimmunoassay and effect on the biological activities of the growth factor. J Mol Endocrinol. 1989;2:201-206. (Pubitemid 19117456)
18. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods [published correction appears in Stat Med. 1999; 18:1293]. Stat Med. 1998;17:873-890. (Pubitemid 28185166)
19. Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab. 2009;94:523-527.
20. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly. Clin Endocrinol (Oxf). 2008;68:473-480. (Pubitemid 351257869)
21. Bevan JS, Newell-Price J, Wass JA, et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf). 2008;68:343-349. (Pubitemid 351257850)
22. Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Horm Res. 2004;62: 227-232. (Pubitemid 39551736)
23. Ronchi CL, Boschetti M, Degli Uberti EC, et al (Italian Multicenter Autogel Study Group in Acromegaly). Efficacy of a slow-release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf). 2007;67:512-519. (Pubitemid 47416307)
24. Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab. 2006; 91:1239-1245.
25. Melmed S, Colao A, Barkan A, et al (Acromegaly Consensus Group). Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94: 1509-1517.